Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCUE71)

Drug Name
PRGN-3005 Drug Info
Indication
Disease Entry ICD 11 Status REF
Refractory hematologic malignancy 2A85.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMCUE71

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ovarian carcinoma antigen CA125 (MUC16) TTC1PS3 MUC16_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Ovarian carcinoma antigen CA125 (MUC16) DTT MUC16 1.138 1.585 1.322 1.322
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Refractory hematologic malignancy
ICD Disease Classification 2A85.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ovarian carcinoma antigen CA125 (MUC16) DTT MUC16 4.86E-04 5.02 2.6
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03907527) Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Precigen.